 SLAMF7 is a self-ligand over-expressed in plasma cells of multiple myeloma patients.Elotuzumab stimulates NK cells to release granzyme through blocking SLAMF7, through triggering antibody-dependent cellular cytotoxicity (ADCC), and through NK cell activation via Ewing’s sarcoma-associated transcript 2 (EAT-2).EAT-2 is known to bind to phosphorylated tyrosines on ITSMs and alter cytokine production.